Summary
This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid cancers. They are investigating different doses in order to find the safest and most effective one.
The study has two experimental treatment arms.
In the SNV4818 monotherapy arm, participants will receive oral, daily doses of SNV4818 as a single agent as part of either dose escalation or dose expansion cohorts.
In the SNV4818 + Fulvestrant combination arm, participants will receive oral, daily doses of SNV4818 in combination with a standard dose of Fulvestrant (given as an injection into the muscle) as part of either dose escalation or dose expansion cohorts.
In both arms, the SNV4818 dose level participants receive will depend upon the study part to which they are assigned. Dose escalation participants will be assigned to small cohorts of ascending SNV4818 dose levels. Dose expansion participants will receive one of the SNV4818 dose levels recommended for further evaluation.